Certara, Inc. 8-K

What Happened

• Certara, Inc. filed an 8-K on May 11, 2026 (Item 2.02) furnishing a press release with its financial results for the three-month period ended March 31, 2026. The press release is attached as Exhibit 99.1.
• Separately (Item 8.01), Certara confirmed that it entered a Purchase Agreement with Veristat on April 21, 2026 and completed the sale of its global medical writing and related regulatory services business to Veristat on May 8, 2026.

Key Details

• Sale closed May 8, 2026 pursuant to the April 21, 2026 Purchase Agreement with Veristat.
• Cash consideration of $85.0 million, subject to customary adjustments in the Purchase Agreement.
• $15.0 million placed in escrow to be released upon satisfaction of certain post-closing covenants.
• Potential additional contingent cash consideration (earn-out) of up to $35.0 million based on the Business’s post-closing financial performance.

Why It Matters

• The 8-K combines two material items: the company’s quarterly results disclosure and a completed divestiture. The sale converts the medical writing business into near-term cash proceeds (with some escrow and contingent future payments), which can affect Certara’s liquidity and capital allocation.
• Investors should review the May 11, 2026 press release for the detailed Q1 financial metrics and monitor future disclosures for any adjustments, escrow releases, or earn-out realizations tied to the sale.